Protein A beads were co-incubated overnight at 4°C with A431 lysates and pre-immune or immune sera. As positive controls for HER1 and HER2 precipitation respectively, 2μg of nimotuzumab and trastuzumab were used instead serum. The precipitated was extensively washed, applied to 7.5% SDS-PAGE, transferred to PVDF membranes and immunobloting was performed to detect HER2 and HER1 with specific antibodies as described.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.